1. Bachmayr-Heyda, A., Aust, S., Heinze, G., Polterauer, S., Grimm, C., Braicu, E. I., Sehouli, J., Lambrechts, S., Vergote, I., Mahner, S., Pils, D., Schuster, E., Thalhammer, T., Horvat, R., Denkert, C., Zeillinger, R., & Castillo-Tong, D. (2013). Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients-a study of the OVCAD consortium. BMC Cancer, 13, 422. https://doi.org/10.1186/1471-2407-13-422
2. Brock, K. (2019). trialr: Bayesian clinical trial designs in R and Stan. arXiv preprint arXiv:1907.00161
3. Brock, K., Billingham, L., Copland, M., Siddique, S., Sirovica, M., & Yap, C. (2017). Implementing the EffTox dose-finding design in the Matchpoint trial. BMC Medical Research Methodology, 17(1), 1–15.
4. Brunk, H. D., Barlow, R. E., Bartholomew, D. J., & Bremner, J. M. (1972). Statistical inference under order restrictions.(the theory and application of isotonic regression). Missouri University of Columbia Department of Statistics.
5. Liu, S., Guo, B., & Yuan, Y. (2018). A Bayesian phase I/II trial design for immunotherapy. Journal of the American Statistical Association, 113(523), 1016–1027.